Clinical Trial Update: Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating intradermal delivery of an influenza A H7N9 vaccine using a high-density microarray patch (HD-MAP) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Virus Infection H7n9 Subtype

Drugs mentioned

• HD-MAP H7N9 influenza vaccine

Snippet

Sponsor: Vaxxas Pty Ltd | Conditions: H7N9 Influenza | Phase 1 | Status: COMPLETED